Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb 23:10:1155-1164.
doi: 10.2147/OTT.S127955. eCollection 2017.

Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas

Federica Recine  1 , Alberto Bongiovanni  1 , Nada Riva  1 , Valentina Fausti  1 , Alessandro De Vita  1 , Laura Mercatali  1 , Chiara Liverani  1 , Giacomo Miserocchi  1 , Dino Amadori  1 , Toni Ibrahim  1
Affiliations
Review

Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas

Federica Recine et al. Onco Targets Ther. .

Abstract

Soft tissue sarcomas (STS) represent a variety of tumors of mesenchymal origin, accounting for about 1% of all adult cancers. This group of tumors comprises over 60 different histotypes with different biology showing different sensitivity to therapeutic agents. For decades, the standard first-line systemic treatment of metastatic STS has comprised anthracycline based-chemotherapy. Second-line therapy options include agents such as ifosfamide, gemcitabine, and pazopanib, but the optimal sequential therapy for the management of metastatic disease has yet to be defined. Trabectedin is one of the new molecules approved for patients in progression after first-line chemotherapy with anthracyclines or for those unfit for these agents. The compound is characterized by multiple potential mechanisms of action combining cytotoxic, targeted, and immunological effects. This article takes an in-depth look at the role of trabectedin in the management of metastatic STS, including L-sarcoma and non-L-sarcoma.

Keywords: L-sarcomas; chemotherapy; histotypes; non-L-sarcomas; soft tissue sarcoma.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;66(1):5–29. - PubMed
    1. Fletcher CD. The evolving classification of soft tissue tumours – an update based on the new 2013 WHO classification. Histopathology. 2014;64(1):2–11. - PubMed
    1. Schwartz GK. Trabectedin and the L-Sarcomas: a decade-long odyssey. J Clin Oncol. 2016;34(8):769–771. - PubMed
    1. Ducimetière F, Lurkin A, Ranchère-Vince D, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011;6(8):e20294. - PMC - PubMed
    1. The ESMO/European Sarcoma Network Working Group Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii102–iii112. - PubMed

LinkOut - more resources